Treatment Efficacy and Safety of Ethanol Ablation for Thyroglossal Duct Cysts: A Comparison with Surgery

2016 ◽  
Vol 27 (7) ◽  
pp. 2708-2716 ◽  
Author(s):  
Mi Sun Chung ◽  
Jung Hwan Baek ◽  
Jeong Hyun Lee ◽  
Young Jun Choi ◽  
Jong Ho Yoon ◽  
...  
2010 ◽  
Vol 32 (2) ◽  
pp. 306-309 ◽  
Author(s):  
S.M. Kim ◽  
J.H. Baek ◽  
Y.S. Kim ◽  
J.Y. Sung ◽  
H.K. Lim ◽  
...  

Author(s):  
Sang Ik Park ◽  
Jung Hwan Baek ◽  
Sae Rom Chung ◽  
Young Jun Choi ◽  
Jeong Hyun Lee ◽  
...  

MedPharmRes ◽  
2020 ◽  
Vol 4 (1) ◽  
pp. 18-22
Author(s):  
Van Bang Nguyen ◽  
Van Vy Hau Nguyen ◽  
Binh Thang Tran ◽  
Chi Van Le

Background: In Vietnam, surgery or aspiration is preferred to treat thyroid cysts however each of them still have limitations. Purposes of this study were to evaluate the efficacy and safety of ethanol ablation in treating thyroid cysts and determine factors that predict the outcome of treatment. Methods: This prospective study was approved by the Ethics Committee of the Institutional Review Board of Family hospital and written informed consent for procedures was obtained. From May 2018 to March 2019, 23 patients who underwent treatment for thyroid cysts by EA were enrolled in this study and were followed up for 1 month at Family hospital. The primary endpoint was efficient after one month as the volume reduction ratio was ≥ 50%. Secondary endpoints were improvements in symptoms, cosmetic scores, and safety. Multiple logistic regression analysis was used. Results: In the finding, from May 2018 to March 2019, only 17 patients who matched inclusion criteria were included in the analyst, including 7 purely thyroid cysts, and 10 predominantly cystic nodules. Mean volume decreased significantly from 5.21 ± 3.37 ml to 2.35 ± 2.52 ml in corresponding to 52.87% of volume reduction with p < 0.05. Ethanol ablation (EA) success rate was 52.90% after 1 month. Symptoms and cosmetic scores were improved significantly. The thyroid function was constant. No adverse events occurred. Purely thyroid cyst was a predictive factor contributing to the success of EA. Conclusion: EA seems likely to be a safe and an efficient therapy for patients who had purely or predominantly cystic thyroid nodules.


1999 ◽  
Vol 4 (2) ◽  
pp. 47-54 ◽  
Author(s):  
Mitsuhide Yoshida ◽  
Hiroyuki Kumamoto ◽  
Kiyoshi Ooya ◽  
Hideaki Mayanagi

2014 ◽  
Vol 6 (1) ◽  
pp. 129-131
Author(s):  
Mukta Rawte ◽  
Nabaneet Majumder ◽  
Virendra Dafle ◽  
Pramod Purohit

Thyroglossal duct cysts are most common congenital anomalies in thyroid development and are usually presented with midline neck swelling. The co-existence of carcinoma in thyroglossal duct cyst’s is extremely rare. We, herein present a case of primary papillary carcinoma arising from thyroglossal duct cyst in a 45 year old woman. DOI: http://dx.doi.org/10.3126/ajms.v6i1.9305 Asian Journal of Medical Sciences Vol.6(1) 2015 129-131


2021 ◽  
Vol 59 (1) ◽  
pp. 8-11
Author(s):  
Dilyara Kaidarova ◽  
Oxana Shatkovskaya ◽  
Zaure Dushimova ◽  
Bakytzhan Ongarbayev

Relevance: Prostate cancer (PC) is one of the most common malignant neoplasms in the male population. The widespread introduction of modern diagnostic methods and the determination of prostate-specific antigen (PSA) levels have increased the number of detected cases of localized and locally advanced PC forms. However, in some patients treated with radical methods and long-term androgen deprivation therapy (ADT), the disease continues to progress in the form of an increase in PSA levels with castration testosterone values and with no distant metastases. Such a course of the disease is referred to as non-metastatic castration-resistant prostate cancer (nmCRPC). Purpose: The article reports the results of a meeting of the Expert Council arranged by the Kazakh Research Institute of Oncology and Radiology on December 25, 2020, on non-metastatic castration-resistant prostate cancer diagnostics and treatment. Results: Large clinical studies highlight the critical importance of controlling the PSA doubling time as the main prognostic factor for an unfavorable outcome to increase patient survival and prevent the development of distant metastases. Based on the results of large randomized studies, experts recommended using new-generation androgen receptor antagonists in combination with ongoing ADT to improve the clinical outcomes in nmCRPC patients at high risk of metastatic progression. The Expert Council was presented with the data of a registration clinical study on darolutamide efficacy and safety. The advantages of introducing this drug into clinical practice to expand the choice of therapeutic options were identified. Personalized adjustment of a treatment regimen will increase the treatment efficacy and ensure higher survival in this category of patients. Conclusion: Increasing survival as the main objective in treating nmCRPC patients requires improved diagnostics through regular controlling of testosterone and PSA levels, calculation of PSA doubling time, and the use of radiological diagnostic methods to rule out distant metastases. The choice of therapy in patients at high risk of metastasis shall consider the patient’s status and the treatment efficacy and safety balance.


2020 ◽  
Vol 27 (3) ◽  
pp. 58-67
Author(s):  
Yu. V. Shubik ◽  
M. M. Medvedev ◽  
M. A. Baturova ◽  
A. E. Rivin

The indications for Holter monitoring, which are included in the new Russian guidelines on cardiac arrhythmias and conduction disturbances, are considered. Possibilities of the diagnostic approaches of arrhythmias, management algorithms and treatment efficacy and safety monitoring are discussed.


Sign in / Sign up

Export Citation Format

Share Document